Trial Profile
Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs Niraparib (Primary) ; Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Adverse reactions
- Acronyms NiraRad
- 16 Nov 2022 Status changed from active, no longer recruiting to completed.
- 02 Nov 2022 Results assessing safety of niraparib in combination with Radium-223 for the treatment of metastatic castrate resistant prostate cancer in men without known BRCA mutations published in the Clinical Cancer Research
- 07 Sep 2022 Planned End Date changed from 1 Nov 2021 to 1 Dec 2022.